5 research outputs found

    vtRNA1-1 induced mitoxantrone independent with the existence of MVP.

    No full text
    <p>(A) The efficiency of MVP or vtRNA1-1 knockdown was detected by semiquantitative western blot or qRT-PCR. (B) DOX sensitivity to MCF-7 cells with or without vtRNA1-1 knockdown was detected. (C) Immunofluorescence imaging was performed to detect the sub-cellular localization of DOX with or without vtRNA1-1 knockdown.</p

    vtRNA1-1 expression tightly regulates the expressing level of GAGE6 in MCF-7 and MCF-7/MR.

    No full text
    <p>(A) RNA-IP assay confirmed the specific binding of PSF to vtRNA1-1 through it RBD in vivo. RT-qPCR (B) and semi-quantitative western blot (C) presents the expressing changes in the mRNA and protein level of GAGE6 in MCF-7 and MCF-7/MR. Chromatin immunoprecipitation assays present that the binding capacity of PSF to GAGE6’s promoter region affected by vtRNA1-1 in MCF-7 (D) or MCF-7/MR (E). RT-qPCR (F) and Semiquantitative western blot (G) present the mRNA and protein levels affected by the ectopic expression of vtRNA1-1 in MCF-7 or MCF-7/MR. *P<0.05.</p

    vtRNA1-1 promotes the tumor formation and enhances the chemoresistance of DOX in vitro.

    No full text
    <p>(A) After transfection of vtRNA1-1, RBD or vtRNA1-1/RBD, sensitivity to DOX was measured in MCF-7 cells. (B) the expressing levels of GAGE6 and PSF after the DOX treatment were detected in MCF-7 transfected with vtRNA1-1, RBD or vtRNA1-1/RBD and the relative folds were qualified (C). (D) ChIP was performed to detect the binding of PSF to GAGE6 promoter in MCF-7 transfected with vtRNA1-1, RBD or vtRNA1-1/RBD after DOX exposure. CCK-8 assay (E) or PI staining (F) was performed to detect cell viability in MCF-7 transfected with vtRNA1-1 after DOX exposure. *P<0.05.</p

    VRNA binds to PSF on its RNA binding domain (RBD) and releases GAGE6 promoter from PSF in vitro.

    No full text
    <p>(A) Northern blot was performed to detect the existence of vtRNA1-1, 1–2, 1–3 or 2–1. (B) qRT-PCR analysis was performed to quantify the relative amount of vtRNA1-1, 1–2, 1–3 or 2–1 normalized to 5.8S rRNA. (C) EMSA analysis was performed the binding of vtRNA1-1, 1–2, 1–3 or 2–1 to purified PSF in vitro. (D) The specific binding of vtRNA1-1 to RBD of PSF was detected. (E) the competitive binding of vtRNA1-1 to PSF against GAGE6 promoter fragment was analyzed.</p

    The effects of vtRNA1-1 in cell proliferation and colony formation in a PSF-dependent way.

    No full text
    <p>Cell curve assays were performed to identify the association of vRNA with PSF (A, left panel), RBD or DBD (B, right panel) on affecting the cell proliferation in MCF-7. (B) EdU staining was performed to further confirm the effect of vRNA on cell proliferation. (C) Soft agar assay was performed to present vRNA’s effect on colony formation in MCF-7. *P<0.05.</p
    corecore